• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tumor Mutation Burden: Is It Ready for the Clinic?

作者信息

Goto Yasushi

机构信息

Yasushi Goto, National Cancer Center Hospital, Tokyo, Japan.

出版信息

J Clin Oncol. 2018 Oct 20;36(30):2978-2979. doi: 10.1200/JCO.2018.79.3398. Epub 2018 Sep 4.

DOI:10.1200/JCO.2018.79.3398
PMID:30179566
Abstract
摘要

相似文献

1
Tumor Mutation Burden: Is It Ready for the Clinic?肿瘤突变负荷：它准备好应用于临床了吗？
J Clin Oncol. 2018 Oct 20;36(30):2978-2979. doi: 10.1200/JCO.2018.79.3398. Epub 2018 Sep 4.
2
Lung Cancer with a High Tumor Mutational Burden.肿瘤突变负荷高的肺癌
N Engl J Med. 2018 Sep 13;379(11):1093. doi: 10.1056/NEJMc1808566.
3
Lung Cancer with a High Tumor Mutational Burden.肿瘤突变负荷高的肺癌
N Engl J Med. 2018 Sep 13;379(11):1093-1094. doi: 10.1056/NEJMc1808566.
4
Are We Ready for Histology-Driven Stereotactic Ablative Radiotherapy?
J Thorac Oncol. 2018 Oct;13(10):1441-1442. doi: 10.1016/j.jtho.2018.07.095.
5
[Exploring the Possibility of New Biomarkers of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer (NSCLC)].
Gan To Kagaku Ryoho. 2017 Sep;44(9):763-766.
6
Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.晚期非小细胞肺癌患者中，循环游离表皮生长因子受体（EGFR）突变浓度的定量与肿瘤负荷相关。
Lung Cancer. 2017 Jul;109:124-127. doi: 10.1016/j.lungcan.2017.05.005. Epub 2017 May 13.
7
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.基于血液的肿瘤突变负担可预测接受阿替利珠单抗治疗的非小细胞肺癌患者的临床获益。
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
8
Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?非小细胞肺癌患者程序性死亡配体1检测：准备好进入黄金时期了吗？
Cancer Cytopathol. 2017 Aug;125(8):591-593. doi: 10.1002/cncy.21882. Epub 2017 Jun 16.
9
Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.基于生物标志物驱动的治疗分配的非小细胞肺癌临床试验：无论准备好与否，我们来了。
Crit Rev Oncog. 2015;20(5-6):339-47. doi: 10.1615/CritRevOncog.v20.i5-6.70.
10
Response to Dahele and Senan.对达赫勒和塞纳恩的回应。
Radiother Oncol. 2013 Oct;109(1):180-1. doi: 10.1016/j.radonc.2013.08.039. Epub 2013 Oct 12.

引用本文的文献

1
Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.基线肿瘤负荷可预测晚期非小细胞肺癌患者一线化疗免疫治疗的疗效：两项3期随机安慰剂对照试验的结果
BMC Cancer. 2025 Aug 27;25(1):1380. doi: 10.1186/s12885-025-14755-z.
2
Development and validation of a novel T cell proliferation-related prognostic model for predicting survival and immunotherapy benefits in melanoma.开发和验证一种新型与 T 细胞增殖相关的预后模型，以预测黑色素瘤患者的生存和免疫治疗获益。
Aging (Albany NY). 2023 May 24;15(10):4444-4464. doi: 10.18632/aging.204748.
3
Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
免疫检查点抑制剂治疗小细胞肺癌患者的生物标志物和影响因素：一项荟萃分析。
Cancer Med. 2023 May;12(10):11211-11233. doi: 10.1002/cam4.5800. Epub 2023 May 10.
4
CAR T-cells for colorectal cancer immunotherapy: Ready to go?嵌合抗原受体 T 细胞治疗结直肠癌免疫疗法：准备就绪了吗？
Front Immunol. 2022 Nov 15;13:978195. doi: 10.3389/fimmu.2022.978195. eCollection 2022.
5
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.携带FAT1突变的黑色素瘤和非小细胞肺癌患者免疫检查点抑制剂治疗效果良好。
NPJ Precis Oncol. 2022 Jun 23;6(1):46. doi: 10.1038/s41698-022-00292-6.
6
ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma Pan-Carcinoma Synthesis.膜联蛋白A2假基因2：卵巢浆液性囊腺癌全癌综合分析中的一种潜在免疫及预后标志物
Front Oncol. 2022 Feb 8;12:818977. doi: 10.3389/fonc.2022.818977. eCollection 2022.
7
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.非小细胞肺癌患者的数字基因表达分析显示出强烈的免疫压力，导致免疫治疗下的免疫逃逸。
BMC Cancer. 2022 Jan 7;22(1):46. doi: 10.1186/s12885-021-09111-w.
8
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.肿瘤突变评分比肿瘤突变负担在预测非小细胞肺癌免疫治疗反应方面更具优势。
Cancer Immunol Immunother. 2021 Aug;70(8):2367-2378. doi: 10.1007/s00262-021-02868-w. Epub 2021 Feb 3.
9
Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?肉瘤中的免疫检查点抑制疗法：隧道尽头有曙光吗？
Cancers (Basel). 2021 Jan 19;13(2):360. doi: 10.3390/cancers13020360.
10
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy.阴茎癌中的免疫微环境及免疫治疗原理
J Clin Med. 2020 Oct 17;9(10):3334. doi: 10.3390/jcm9103334.